| | AstraZeneca and MMV Join Efforts in the Fight Against Malaria | | | AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria. The agreement will initially allow MMV access to AstraZeneca’s extensive compound library. MMV will seek to identify promising compounds with the potential to treat malaria, including drug resistant strains of the disease. AstraZeneca CEO David Brennan announced the collaboration at the Fortune/TIME/CNN Global Forum in Cape Town, South Africa. | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment